The Secrets of a Successful Clinical Trial: Compliance, Compliance, and Compliance
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The high failure rate of drugs in clinical trials, especially in the later stages of development, is a significant contributor to the costs and time associated with bringing new molecular entities to market. These costs, estimated to be in excess of $1.5 billion when capitalized over the ten to fifteen years required to develop a new chemical entity, are one of the principal drivers responsible for the ongoing retrenchment of the pharmaceutical industry. Therapeutic areas such as psychiatry, now deemed very high risk, have been widely downsized, if not abandoned entirely, by the pharmaceutical industry. The extent to which patient noncompliance has marred clinical research has in some cases been underestimated, and one step to improving the design of clinical trials may lie in better attempts to analyze patient compliance during drug testing and clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“Nevertheless, drug development remains a high cost and risky undertaking (1, 2), and if a compound does not elicit the desired efficacy signal in the clinic, blame is most often cast on the inability to appropriately interrogate the targets, and particularly on the lack of translational fidelity of animal models (3).”
BackgroundA Study of the Natural History of Back Pain: Part I
ROLAND, M., & MORRIS, R. (1983) · Spine · doi:10.1097/00007632-198303000-00004 · Cited by 3,395
Is Pharma Running Out of Brainy Ideas?
Miller, G. (2010) · Science · doi:10.1126/science.329.5991.502 · Cited by 284
Cited by
Moser, W., Schindler, C., & Keiser, J. (2017) · BMJ · doi:10.1136/bmj.j4307 · Cited by 350
“18 89 Hence, future randomised controlled trials should follow a harmonised design to reduce confounders, as suggested by WHO, 18 which will yield improved summary estimates of efficacy of anthelmintic drugs.”
BackgroundDauphin-Ducharme, P., Yang, K., Arroyo-Currás, N., Ploense, K. L., Zhang, Y., Gerson, J., Kurnik, M., Kippin, T. E., Stojanovic, M. N., & Plaxco, K. W. (2019) · ACS Sensors · doi:10.1021/acssensors.9b01616 · Cited by 280
Mitigating the Effects of Nonadherence in Clinical Trials
Shiovitz, T. M., Bain, E. E., McCann, D. J., Skolnick, P., Laughren, T., Hanina, A., & Burch, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.689 · Cited by 114
Self-citationMartin-Cantero, A., Reijnierse, E. M., Gill, B. M. T., & Maier, A. B. (2021) · Nutrition Reviews · doi:10.1093/nutrit/nuaa064 · Cited by 58
Metadata
- Authors
- Czobor, P., & Skolnick, P.
- Venue
- Molecular Interventions
- Publisher
- CLOCKSS Archive
- Published
- 2011-04-01
- Volume
- 11
- Issue
- 2
- Pages
- 107-110
- ISSN
- 1534-0384 (ISSN-L)
- OpenAlex
- W2022928755
- Cited by
- 59
- References
- 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.